CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 72 enrolled
Drug / intervention
pregabalin +2 moredrug
Likely dose
pregabalin 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00599638
NCT00599638Phase 2Completed
CompareCT.gov

A TWO WEEK DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER STUDY TO COMPARE THE EFFICACY AND SAFETY OF A PREGABALIN/PF-00489791 COMBINATION VERSUS PREGABALIN ALONE IN PATIENTS WITH POST-HERPETIC NEURALGIA

Pfizer·interventional·Posted Jan 24, 2008·Updated Aug 5, 2021

In Brief

A Phase 2 clinical trial evaluating pregabalin, pregabalin/PF-00489791, and 1 other intervention for Postherpetic Neuralgia. Completed, enrolled 72 participants across 39 sites.

Detailed Summary

Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug. This study will compare the efficacy of pregabalin when administered with an experimental drug PF-00489791, in patients with post-herpetic neuralgia. The efficacy of this combination will be compared to pregabalin alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostherpetic Neuralgia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 24, 2008
Enrollment StartApr 9, 2008
Primary CompletionDec 16, 2008
Study CompletionDec 23, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.4 years ago

Interventions

pregabalindrug

75mg bid titrating to 150mg bid on day 4

pregabalin/PF-00489791drug

Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4

Placebodrug

Placebo